Peripheral neuropathy associated with fluoroquinolones
Peripheral neuropathy associated with fluoroquinolones
复制标题
DOI：
10.1345/aph.1z429
复制
发表时间：
2001-12-01
影响因子：
2.9
通讯作者：
Cohen, JS
中科院分区：
文献类型：
--
作者：
Cohen, JS
目的：调查氟喹诺酮类药物相关的不良事件，包括周围神经系统（PNS）症状张贴在互联网Websites.METHODS：情况下，获得了协助的网站成员形成的人持续氟喹诺酮类药物相关的事件。所获得的信息符合MedWatch的标准，每个报告的情况下进行了评估，使用Naranjo概率scale.RESULTS：在以往的报告表明，氟喹诺酮类药物相关的PNS事件是温和的，短期的，36的45例报告严重的事件，通常涉及多个器官系统。尽管许多新病例仍在发展，但71%的病例症状持续了三个月以上，58%的病例持续了一年以上。不良事件的发生通常很快，15例（33%）事件在开始治疗后24小时内开始，26例（58%）在72小时内开始，38例（84%）在1周内开始。氟喹诺酮类药物60个疗程;规定：左氧氟沙星（n = 33例），环丙沙星（n = 11），氧氟沙星（n = 6），洛美沙星（n = 1），trovaflavin（n = 1）;在8例相同的抗生素处方twice.CONCLUSIONS：这些情况表明氟喹诺酮类抗生素和严重的，长期的不良反应，涉及PNS以及其他器官系统之间可能存在关联。这些病例的严重程度可能反映了与通常报告给制药公司或MedWatch的不同人群，这些病例通常来自医疗保健提供者。相比之下，互联网网站可以为遇到不良反应但尚未迅速解决的患者提供论坛。需要进一步研究。同时，氟喹诺酮类药物治疗期间出现PNS症状应立即停用药物。
OBJECTIVE: To survey cases of fluoroquinolone-associated adverse events that included peripheral nervous system (PNS) symptoms posted on Internet Web sites.METHODS: Cases were obtained with the assistance of members of Web sites formed by people sustaining fluoroquinolone-related events. Information obtained met the standards of MedWatch, and each reported case was assessed using the Naranjo probability scale.RESULTS: In contrast to previous reports suggesting that fluoroquinolone-associated PNS events are mild and short-term, 36 of the 45 cases reported severe events that typically involved multiple organ systems. Although many newer cases are still evolving, symptoms had lasted more than three months in 71% of cases and more than one year in 58%. Onset of adverse events was usually rapid, with 15 (33%) events beginning within 24 hours of initiating treatment, 26 (58%) within 72 hours, and 38 (84%) within one week. Sixty courses of fluoroquinolones; were prescribed: levofloxacin (n = 33 cases), ciprofloxacin (n = 11), ofloxacin (n = 6), lomefloxacin (n = 1), trovafloxacin (n = 1); in eight cases the same antibiotic was prescribed twice.CONCLUSIONS: These cases suggest a possible association between fluoroquinolone antibiotics and severe, long-term adverse effects involving the PNS as well as other organ systems. The severity of these cases may reflect a different population than typically reported to drug companies or MedWatch, which often originate from healthcare providers. In contrast, Internet Web sites may provide a forum for patients experiencing adverse effects that have not resolved promptly. Further study is warranted. Meanwhile, the occurrence of PNS symptoms during fluoroquinolone therapy should prompt immediate discontinuation of the agent used.